EP1940417A4 - Méthode de traitement d'une diarrhée associée à clostridium difficile - Google Patents

Méthode de traitement d'une diarrhée associée à clostridium difficile

Info

Publication number
EP1940417A4
EP1940417A4 EP06826544A EP06826544A EP1940417A4 EP 1940417 A4 EP1940417 A4 EP 1940417A4 EP 06826544 A EP06826544 A EP 06826544A EP 06826544 A EP06826544 A EP 06826544A EP 1940417 A4 EP1940417 A4 EP 1940417A4
Authority
EP
European Patent Office
Prior art keywords
clostridium difficile
associated diarrhea
treating clostridium
treating
diarrhea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06826544A
Other languages
German (de)
English (en)
Other versions
EP1940417A2 (fr
Inventor
Pamela Sears
Youe-Kong Shue
Starr Louise Miller-Shangle
Robert Brian Walsh
Farah Babakhani
Yu-Hung Chiu
Alex Romero
Sherwood Gorbach
Thomas John Louie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Optimer Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Optimer Pharmaceuticals LLC filed Critical Optimer Pharmaceuticals LLC
Publication of EP1940417A2 publication Critical patent/EP1940417A2/fr
Publication of EP1940417A4 publication Critical patent/EP1940417A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP06826544A 2005-10-21 2006-10-23 Méthode de traitement d'une diarrhée associée à clostridium difficile Withdrawn EP1940417A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72913505P 2005-10-21 2005-10-21
US74964105P 2005-12-12 2005-12-12
PCT/US2006/041436 WO2007048059A2 (fr) 2005-10-21 2006-10-23 Méthode de traitement d'une diarrhée associée à clostridium difficile

Publications (2)

Publication Number Publication Date
EP1940417A2 EP1940417A2 (fr) 2008-07-09
EP1940417A4 true EP1940417A4 (fr) 2010-07-07

Family

ID=37963388

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06826544A Withdrawn EP1940417A4 (fr) 2005-10-21 2006-10-23 Méthode de traitement d'une diarrhée associée à clostridium difficile

Country Status (8)

Country Link
EP (1) EP1940417A4 (fr)
JP (1) JP2009512691A (fr)
KR (1) KR101399621B1 (fr)
CN (2) CN102503994A (fr)
AU (1) AU2006304868B2 (fr)
CA (1) CA2626698C (fr)
HK (1) HK1126410A1 (fr)
WO (1) WO2007048059A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906489B2 (en) 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
TWI523654B (zh) 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
JO3464B1 (ar) 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd التركيبات الخاصة بمركبات التياكوميسين
CN104846044B (zh) * 2014-02-17 2019-02-01 上海医药工业研究院 一种提高非达霉素产量的发酵培养基
CN105237599B (zh) * 2015-10-09 2018-10-02 华北制药集团新药研究开发有限责任公司 闰年霉素a4晶体及其制备方法
CN107970253B (zh) * 2017-10-25 2020-05-26 中山大学 台勾霉素衍生物在制备治疗寨卡病毒感染引起的相关疾病和/或症状的药物中的应用
CN107714713B (zh) * 2017-10-25 2020-05-26 中山大学 台勾霉素衍生物在制备治疗登革病毒感染引起的相关疾病和/或症状的药物中的应用
EP4242295A3 (fr) * 2018-06-07 2023-10-18 Artugen Therapeutics Ltd. Souche de b. amyloliquefaciens et utilisation thérapeutique

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583115A (en) * 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
WO2005112990A2 (fr) * 2004-05-14 2005-12-01 Optimer Pharmaceuticals, Inc. Traitement de maladies consecutives a un traitement antibiotique
WO2006085838A1 (fr) * 2005-01-31 2006-08-17 Optimer Pharmaceuticals, Inc. Macrocycles a 18 chainons et leurs analogues

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4918174A (en) 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
AU2003251902B2 (en) * 2002-07-29 2008-03-06 Merck Sharp & Dohme Llc Tiacumicin production

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583115A (en) * 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
WO2005112990A2 (fr) * 2004-05-14 2005-12-01 Optimer Pharmaceuticals, Inc. Traitement de maladies consecutives a un traitement antibiotique
WO2006085838A1 (fr) * 2005-01-31 2006-08-17 Optimer Pharmaceuticals, Inc. Macrocycles a 18 chainons et leurs analogues

Also Published As

Publication number Publication date
CN101340919A (zh) 2009-01-07
WO2007048059A3 (fr) 2007-05-31
KR20080064177A (ko) 2008-07-08
JP2009512691A (ja) 2009-03-26
EP1940417A2 (fr) 2008-07-09
HK1126410A1 (en) 2009-09-04
AU2006304868A1 (en) 2007-04-26
CA2626698A1 (fr) 2007-04-26
CA2626698C (fr) 2015-12-01
AU2006304868B2 (en) 2013-02-21
CN102503994A (zh) 2012-06-20
KR101399621B1 (ko) 2014-06-18
CN101340919B (zh) 2011-12-07
WO2007048059A2 (fr) 2007-04-26

Similar Documents

Publication Publication Date Title
HK1126410A1 (en) Method of treating clostridium difficile-associated diarrhea
EP1909316A4 (fr) Transistor et procédé de fonctionnement correspondant
GB0521944D0 (en) Method of treating gas
IL185540A0 (en) Compositions and methods for treating acne
IL193014A0 (en) Methods and compositions for treating schizophrenia
EP1803244A4 (fr) Procede de chiffrement
HK1114350A1 (en) An extract for preventing or treating thrombotic diseases
GB0522287D0 (en) Method and compositions
EP1940437A4 (fr) Compositions et procedes pour le traitement de bacteries
IL183889A0 (en) Treatment method
IL198677A0 (en) Compositions and methods for diagnosing, treating , and preventing prostate conditions
EP1860225A4 (fr) Procede de lavage
WO2007140205A3 (fr) Procédés de traitement de fibrose
IL220806A0 (en) Method and compositions for enhancing vascular access
IL191237A0 (en) Compositions and methods for treating thrombocytopenia
EP1982210A4 (fr) Procédé pour créer une interférence, et agencement de brouillage intentionnel
ZA200703100B (en) Method and composition for preventing or treating diarrhea
IL187531A0 (en) Method and composition for treating osteoarthritis
EP1914308A4 (fr) Plante resistant au froid et procede visant a la developper
GB0524927D0 (en) Compositions and method
FI20050145A (fi) Menetelmä biomassan käsittelemiseksi
HK1134947A1 (en) Oven, especially domestic oven and method for operating such an oven
EP2035037A4 (fr) Procédés, compositions, et trousses destinés au traitement de pathologies associées à la toxine shiga
GB0608357D0 (en) Method for treating effluent
EP1959982A4 (fr) Procédés et compositions servant à prévenir et/ou traiter la pancréatite

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080425

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20100609

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/04 20060101ALI20100602BHEP

Ipc: A61K 45/06 20060101ALI20100602BHEP

Ipc: A61K 31/70 20060101AFI20080428BHEP

17Q First examination report despatched

Effective date: 20110216

17Q First examination report despatched

Effective date: 20110302

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: OPTIMER PHARMACEUTICALS, INC.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MERCK SHARP & DOHME CORP.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160202